PUBLICATIONS

1. Kossman CE, Porterfield JG, Straughn AB: Digitalis intoxication.J Tenn Med Assoc70(9): 644-50, 1977.
2. Porterfield J, Glisan G, Schoeneberger A, Verrier R: Effects of prenylamine (Segontin) on susceptibility to spontaneous ventricular arrhythmias during acute coronary artery occlusion and reperfusion in the conscious dog.  Clin Res 27: 196A (abstract), 1979.
3. Porterfield JG, Antman E, Lown B:  Respiratory difficulty after use of disopyramide.    New Engl J Med 303:  584 (letter), 1980.  
4. Podrid J, Schoeneberger A, Lown B, Lampert S, Matos J, Porterfield J, Raeder E, Corrigan E: Use of nonsustained ventricular tachycardia as a guide to antiarrhythmic drug therapy in patients with malignant ventricular arrhythmia.  Am Heart J 105 (2):  181-188, 1983.
5. Porterfield J, Brown S, Simmons D, Goldstein S:  Electro- physiologic effects of long-term lorcainide. PACE 7(3):  475 (abstract), 1984.
6. McGrew F, Coppess M, and Porterfield J:  The initial experience of an activity responsive  cardiac pacemaker. Proceeding of the "Progress in Clinical Pacing," Rome, Italy, December 6, 1984.
7. Porterfield JG, Groshart KD, Golden EB, Iansmith DHS, Dean PJ, Vanderzwaag R: “Amiodarone pulmonary toxicity." Circulation 72 (3):  272 (abstract), 1985.  
8. Porterfield JG, Porterfield LM, Brown S:  Sudden Cardiac Death.  Focus on Critical Care 13:23-31, 1986.
9. Porterfield JG, Simmons D, Coppess M, Filipovich M, Combs W, Strong S:  New techniques for programmed electrical stimulation.  Clinical Progress in Electrophysiology and Pacing 4:65 (abstract), 1986.
10. Porterfield JG, Simmons D, Coppess M, Combs W, Filipovich M, Strong S:  Programmed electrical stimulation in patients with cardiomyopathy. Clinical Progress in  Electrophysiology and Pacing 4:66 (abstract), 1986.
11. Porterfield JG, Iansmith DH, Kossmann CE:  Contemporary cardiac pacing.  Journal of the Tennessee Medical Association 79 (8):  481-490, 1986.
12. Dean PJ, Groshart KD, Porterfield JG, Iansmith DH, Golden EB:  Amiodarone-associated  pulmonary toxicity.  Am J Clin Path 87 (1):  7-13, 1987.
13. Singh BH, Kaplinsky E, Kirsten E, Guerrero J, and the Propafenone Multi-Center Research Group:  Effects of propafenone on ventricular arrhythmias:  Double-blind, parallel, randomized, placebo-controlled dose-ranging study. Am Heart J  116 (6):  1542-1551, 1988.
14. Porterfield JG, Porterfield L:  Therapeutic efficacy and safety of oral propafenone for atrial fibrillation.  Am J Cardiol 63 (1):  114-116, 1989.
15. Porterfield JG, Porterfield LM, Bray L. Long term community hospital experience with the internal defibrillator.  PACE 14 (2): 263-266, 1991.
16. Porterfield JG, Porterfield LM, Bray L, and Sugalski J.  A Prospective study utilizing a  transtelephonic electrocardiographic transmission program to manage patients the first   several months post AICD implant.  PACE 14 (2): 308-311, 1991.
17. Porterfield JG, Porterfield LM, Bray L.  Ninety-six episodes of spontaneous ventricular tachycardia in one week:  Success of ramp pacing by a pacer-cardioverter- defibrillator. PACE 14 (10): 1440-1443, 1991. 
18. Herre JM, Cannom DS, Fogoros RN, and the VENTAK PRx Phase I Investigator Group. Initial multicenter clinical experience with a multifunctional implantable pacemaker defibrillator.  Circulation 84 (4): 428 (abstract), 1991.
19. Porterfield JG, Porterfield LM, Strong SB.  Propafenone therapy for malignant ventricular arrhythmias.  J Invas Cardiol; 4(3):131-135, 1993.
20. Porterfield JG and Porterfield LM.  Signal-averaged electrocardiograms; A new     noninvasive tool to identify patients at risk for sudden cardiac death.  Patient Care Jan 30: 73-80, 1993.
21. Winkle RA, Fain ES, Sweeney MB, Senelly KM, and the Cadence Investigators.  Survival  in patients with ventricular tachyarrhythmias treated with programmable tiered therapy implantable defibrillators.  J Am Coll Cardiol 19 (3): 209A (abstract), 1992.
22. Winkle RA, Fain ES, Hardage ML, Senelly KM, and the Cadence Investigators.  The   value and usage of programmability in a tiered therapy defibrillator.  J Am Coll Cardio  19 (3): 365A  (abstract), 1992.
23. Rahul Mehra, Norenberg MS, Degroot P, PCD Investigators. Multicenter clinical results with an implantable defibrillator utilizing transvenous leads.  PACE 15 (4): 566, 1992.
24. Porterfield JG, Porterfield LM, Smith BA, et al.  Conversion rates of induced versus spontaneous ventricular tachycardia by a third generation cardioverter defibrillator.    EUR JCPE 2 (2): 118A (abstract), 1992.
25. Porterfield JG, Porterfield LM, Smith BA, et al.  Clinical experience with three different third generation cardioverter defibrillators.  EUR JCPE 2 (2): 120A (abstract), 1992.
26. Porterfield JG, Porterfield LM, Smith BA, et al.  Conversion rates of induced versus spontaneous ventricular tachycardia by a third generation cardioverter defibrillator.  PACE 16 (1): 170-173, 1993.       
27. Saksena S and the PCD Investigators.  Defibrillation thresholds and perioperative    mortality associated with endocardial and epicardial defibrillation lead systems. PACE; 16 (1): 202-207, 1993.
28. Van Wyhe G and US VENTAK PRx Investigator Group.  Survival analysis of a tiered   therapy device: Availability of additional therapy at no compromise of morbidity,           mortality, or sudden death survival.  J Am Coll Cardiol 21 (2): 154A (abstract), 1993.
29. Herre JM for the US VENTAK PRx Investigator Group.  One year follow-up of antitachycardia pacing and low energy cardioversion in a third generation implantable    defibrillator.  J Am Coll Cardiol 21 (2) : 169A (abstract), 1993.
30. Leitch J, Yee R, and the Multicenter PCD Investigators Group.  Predictors of defibrillation efficacy in patients undergoing epicardial defibrillator implantation. 
    J Am Coll Cardiol 21: 1632-1637, 1993. 
31. Porterfield JG, Porterfield, LM. Smith BA, Bray L. Experience with three different third generation cardioverter defibrillators in patients with coronary artery disease or               cardiomyopathy.  Am J Cardiol 72 (3) 301- 304, 1993.
32. Steinhaus DM, Foley L, Knoll K, and PCD Investigators.  Non-thoracotomy defibrillator systems: Who is a candidate?  PACE 16 (4): 185, 1993.
33. Porterfield LM and Porterfield JG.  Digitalis overdose:  A common occurrence.  Critical Care Nurse 13(6): 40-43, 1993.
34. Porterfield JG, Porterfield LM, Snell J.  The usefulness of the third generation defibrillator for the management of a patient with recurrent ventricular arrhythmias. 
    J Invas Cardiol 5(8): 315-318, 1993.
35. Porterfield JG, Porterfield LM. Radiofrequency ablation of a left-sided free-wall accessory pathway: A case study. Critical Care Nurse 13 (2): 46-49, 1993.
36. Porterfield LM, Porterfield JG, Eppes D, et al.  Know your defibrillator:  An instructional computer program.  J Am Coll Cardiol February: 384A (abstract), 1994. 
37. Levine J, Porterfield J, Stark S, et al. Improved intraoperative results with a new hybrid third  generation cardioverter-defibrillator and non-thoracotomy lead system. PACE 17(4): 870 (abstract), 1994.
38. PCD Investigator Group. Clinical outcome of patients with malignant ventricular          tachyarrhythmias and a multiprogrammable implantable cardiovert-defibrillator implanted with or without thoracotomy: An international multicenter study. J Am Coll Cardiol 23: 1521-30, 1994.
39. Reiter MJ, Fain ES, Senelly KM, Robertson AD, and The Cadence Investigators.  Predictors  of device activation for ventricular arrhythmias and survival in patients with implantable  Pacemakers/defibrillators.  PACE 17:1487-1498, 1994.
40. Porterfield JG and Porterfield, LM. A new approach: A single triple electrode system     interfaced with a third generation defibrillator. J Invas Cardiol 6:246-250, 1994.
41. Porterfield LM, Porterfield JG, and Eppes D. Know your defibrillator: An instructional  computer program. Cath-Lab Digest 2:10, 1994.
    
    
42. Porterfield JG, Porterfield LM, Levine J, Luceri RM, Hsai HH. and the Cadence/Endotak IDE Investigators. A prospective study analyzing the safety and efficacy of interfacing a triple electrode defibrillation lead system with a tiered therapy device. Circulation 90:I 497  (abstract), 1994.
43. Hammill SC, Packer DL, Stanton MS, Fetter J, and the Multicenter PCD Investigator Group.  Termination and acceleration of ventricular tachycardia with autodecremental pacing, burst pacing, and cardioversion in patients with an implantable cardioverter defibrillator. PACE 18  (1): 3-10, 1995.
44. Porterfield JG, Porterfield LM, Fiallo LA. Management of ventricular tachycardia with  ablation therapy in a patient with a previously implanted cardioverter defibrillator.
    J Invas Cardiol 7; 53-56: 1995.
45. Porterfield JG, Porterfield LM, and Ali M. ECG Case and Comment:  Arrhythmia after emergency CABG. Patient Care 29; 74-75: 1995.
46. Porterfield JG, and Porterfield LM. ECG Case and Comment: Dig those crazy rhythms. Patient Care 29: 1589: 1995.
47. Zipes DP, Roberts D; for the Pacemaker-Cardioverter-Defibrillator Investigators. Results of  the international study of the implantable cardioverter-defibrillator. Circulation 92;59-65: 1995.
48. Porterfield JG and Porterfield LM.  ECG Case and Comment: A "shock" to the system. Patient Care 29; 181-182: 1995.
49. Porterfield JG, Porterfield LM, Rice KM. ECG Case and Comment:  Refractory atrial    fibrillator: What next?  Patient Care 29; 90-92: 1995.
50. Porterfield JG, and Porterfield LM. The evolution of implantable defibrillator technology. Primary Cardiology 21; 24-32: 1995.  
51. Porterfield JG and Porterfield LM. Circadian patterns of  3,087 patients with supraventricular tachycardias.  J Am Coll Cardiol 27:399A (abstract), 1996.                
52. Porterfield JG, Porterfield LM, Levine JH, et al. Compatibility of a nonthoracotomy lead system with a biphasic implantable cardioverter-defibrillator.  Am J Cardiol 77; 586-590, 1996.
53. Porterfield JG, Porterfield LM, Ali M. A cure for a common arrhythmia.  Patient Care 30; 222-228: 1996. 
54. Bardy GH, Yee R, Jung W for the Active Can Investigators. Multicenter experience with a  pectoral unipolar implantable cardioverter-defibrillator.  J Am Coll Cardiol 28; 400-410, 1996.
55. Mahajan S, Porterfield JG, Porterfield LM, Wells VE and Crump CC. The shocking lung mass: A case report.  PACE 19; 1398-1399, 1996.
56. Porterfield JG, Porterfield LM, Mahajan S. A diagnostic dilemna unraveled.  Patient Care 31; 184-186:  1997.
57. Porterfield JG, Porterfield LM, Easley A, et al. Transtelephonic ICD follow-up:  a new patient-management tool PACE; 20 (Part II):633 (abstract), 1997.
58. Porterfield JG, Porterfield LM, Boko, TE.  Multiple, mysterious syncopal episodes.  Patient Care 32; 185-187, 1998.
59. Porterfield JG, Porterfield LM, Nestor JR. Daily variations in the occurrence of symptomatic supraventricular tachycardia as determined by ambulatory event monitoring.  Am J Cardiol 80; 889-891, 1998.
60. Porterfield JG, Porterfield LM, Nestor JR.  Unexplained Syncope:  What to expect from loop recorders.  Archives des maladies du Coeur et des Vaisseaux 91; 197, 1998.
61. Porterfield JG, Porterfield LM.  Unexplained Syncope:  What to expect from loop recorders. The Journal of Noninvasive Cardiology 3(3); 91-94, 1998.
62. Porterfield JG, Porterfield LM, and Khattak T.  A syncopal episode.  Patient Care 34(6); 137-139, 2000.
63. Porterfield JG, Khattak TA, and Porterfield, LM.  Reversible neurologic deficit in a patient with a pacemaker.  Patient Care 35(5); 98-99, 2001.
64. Porterfield JG, Porterfield LM, Roberts DM, and Butze EA.  Long-term performance of one transvenous lead system for implantable cardioverter-defibrillators. EUROPACE 1; 209 D, 2000.
65. Porterfield JG, Menon V, Porterfield LM.  Should a patient with an internal defibrillator drive?  Patient Care 34; 73-74, 2000.
66. Shaikh K, Porterfield JG, Porterfield LM.  Pacemaker mode switching.  Patient Care 35(7); 120, 2001.
    
    
67. Porterfield JG, Porterfield LM, Khattak T.  Uncommon reaction to a commonly used antibiotic.  Patient Care 34; 138-139, 2000.
68. Higgins SL, herre JM, Epstein AE, Greer GS, Friedman PL, Gleva ML, Porterfield JG, et al.  Focus on Defibrillation: A comparison of Biphasic and Monophasic shocks for external defibrillation.  Prehospital Emergency Care 4; 305-313, 2000
69. Porterfield JG, Porterfield LM, Butze EA, Bryant JL.  Fourteen year experience in patients with implantable cardioverter-defibrillators.  PACE 24(Part II); 674, 2001.
70. Watson AT, Porterfield JG, Porterfield LM.  Sudden cardiac death in a patient with palpitations.  Patient Care 35 (19) 77-79, 2001.
71. Lofton B, Porterfield JG, Porterfield LM.  Idiopathic right sided ventricular tachycardia.  Patient Care (In Press).
72. Shaikh K, Porterfield JG, Porterfield LM.  Inappropriate sinus tachycardia.  Patient Care (In Press).
73. Watson, AT, Porterfield, JG, Porterfield, LM.  Cocaine induced myocardial infarction with subsequent ventricular tachycardia.  Patient Care (In Press).